"Hypoglycemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances which lower blood glucose levels.
| Descriptor ID |
D007004
|
| MeSH Number(s) |
D27.505.696.422
|
| Concept/Terms |
Hypoglycemic Agents- Hypoglycemic Agents
- Agents, Hypoglycemic
- Antihyperglycemics
- Antihyperglycemic Agents
- Agents, Antihyperglycemic
- Hypoglycemic Drugs
- Drugs, Hypoglycemic
- Hypoglycemics
Hypoglycemic Effect- Hypoglycemic Effect
- Effect, Hypoglycemic
- Hypoglycemic Effects
- Effects, Hypoglycemic
Antidiabetics- Antidiabetics
- Antidiabetic Drugs
- Drugs, Antidiabetic
- Antidiabetic Agents
- Agents, Antidiabetic
|
Below are MeSH descriptors whose meaning is more general than "Hypoglycemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypoglycemic Agents".
This graph shows the total number of publications written about "Hypoglycemic Agents" by people in this website by year, and whether "Hypoglycemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2003 | 3 | 0 | 3 |
| 2004 | 4 | 3 | 7 |
| 2005 | 4 | 3 | 7 |
| 2006 | 3 | 5 | 8 |
| 2007 | 8 | 0 | 8 |
| 2008 | 3 | 3 | 6 |
| 2009 | 4 | 4 | 8 |
| 2010 | 9 | 8 | 17 |
| 2011 | 4 | 2 | 6 |
| 2012 | 7 | 1 | 8 |
| 2013 | 12 | 5 | 17 |
| 2014 | 8 | 7 | 15 |
| 2015 | 13 | 5 | 18 |
| 2016 | 5 | 3 | 8 |
| 2017 | 7 | 5 | 12 |
| 2018 | 2 | 2 | 4 |
| 2019 | 4 | 1 | 5 |
| 2020 | 3 | 3 | 6 |
| 2021 | 1 | 3 | 4 |
| 2022 | 3 | 3 | 6 |
| 2024 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypoglycemic Agents" by people in Profiles.
-
Sex-Specific Cardiovascular Risk Factors and Treatment in Females With T2DM and CVD: Developments and Knowledge Gaps. J Clin Endocrinol Metab. 2024 Nov 18; 109(12):e2167-e2177.
-
Cardiovascular and mortality benefits of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide 1 receptor agonists as third-step glucose-lowering medicine in patients with type 2 diabetes: a retrospective cohort analysis. BMJ Open Diabetes Res Care. 2024 May 06; 12(3).
-
Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Ann Intern Med. 2024 May; 177(5):658-666.
-
Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes. N Engl J Med. 2022 09 22; 387(12):1075-1088.
-
Development and validation of prediction models for gestational diabetes treatment modality using supervised machine learning: a population-based cohort study. BMC Med. 2022 09 15; 20(1):307.
-
Screening for Prediabetes and Type 2 Diabetes in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022 09 13; 328(10):968-979.
-
Weight loss and ß-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial. Obesity (Silver Spring). 2022 08; 30(8):1579-1588.
-
Use and Impact of Type 2 Diabetes Prevention Interventions. Am J Prev Med. 2022 10; 63(4):603-610.
-
Association of Glyburide and Subcutaneous Insulin With Perinatal Complications Among Women With Gestational Diabetes. JAMA Netw Open. 2022 Mar 01; 5(3):e225026.
-
Diabetes and pancreatic cancer: recent insights with implications for early diagnosis, treatment and prevention. Curr Opin Gastroenterol. 2021 09 01; 37(5):539-543.